Cardiovascular Systems, Inc. (CSI) (Nasdaq:CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, has been added to the Russell 2000 ® Index. The index measures the performance of the 2,000 largest U.S. companies based on total market capitalization. The Russell Investment Group recently reconstituted its indexes, and Russell 2000 membership went into effect at market close on June 24, 2011, and will remain in place for one year. “Inclusion in the latest Russell 2000 Index recognizes CSI’s growth and enhances our visibility among investors,” said David L. Martin, CSI president and chief executive officer. “Within the last year, we launched our third-generation Stealth 360°™ Orbital PAD System with significant ease-of-use innovations, expanded our wealth of clinical data demonstrating our orbital technology’s superior safety and effectiveness in treating peripheral arterial disease (PAD), and launched our pivotal trial for a coronary application in calcified lesions. Our progress on these fronts positions CSI for strong growth in both the PAD and large underserved coronary markets.” The Russell 2000 Index is constructed to provide a comprehensive, unbiased and stable barometer of the broad market and is completely reconstituted annually to ensure new and growing equities are reflected. Safe Harbor Certain statements in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this press release regarding CSI’s potential strong growth in both the PAD and coronary markets are forward-looking statements. These statements involve risks and uncertainties which could cause results to differ materially from those projected, including but not limited to CSI’s clinical trials; the performance of the Diamondback Systems; the FDA process relating to the coronary application; and other factors detailed from time to time in CSI’s SEC reports, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. CSI encourages you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this release. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, CSI's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this release. The forward-looking statements made in this release are made only as of the date of this release, and CSI undertakes no obligation to update them to reflect subsequent events or circumstances.
About Cardiovascular Systems, Inc.Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s Stealth 360°™, Diamondback 360 ® and Diamondback Predator 360 ® Orbital PAD Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback 360° in August 2007 and for the Stealth 360° in March 2011. To date, more than 46,000 PAD procedures have been performed using the Diamondback 360° in leading institutions across the United States. CSI has also commenced its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its Diamondback 360° System in treating coronary arteries. The coronary system is under clinical investigation and is currently not commercially available in the United States. For more information, visit the company’s website at www.csi360.com.